Recent Progress in the Management of Pulmonary Hypertension
スポンサーリンク
概要
- 論文の詳細を見る
Pulmonary hypertension (PH) is a fatal disease caused by small pulmonary artery obstruction from vascular proliferation and remodeling. PH is characterized by elevated pulmonary arterial pressure and increased pulmonary vascular resistance, frequently leading to right-sided heart failure and death. The classification of PH has been recently updated to include 5 major categories of the disorder, are as: Group 1, pulmonary arterial hypertension (PAH); Group 2, PH due to left heart disease; Group 3, PH due to lung diseases and/or hypoxia; Group 4, chronic thromboembolic PH (CTEPH); and Group 5, others. Recently, significant progress has been made in the understanding of the pathophysiology, diagnosis and treatment of PH. Regarding the pathophysiology of the disorder, direct evidence for Rho-kinase activation in the pulmonary artery from PAH patients has been provided. Regarding diagnosis, optical coherence tomography is useful as a new differential diagnostic tool for distal type CTEPH vs. PAH. Regarding treatment, in addition to the conventional therapy, several new drugs are under clinical trial, including fasudil (a Rho-kinase inhibitor), riosiguat (a soluble guanylate cyclase activator), and imatinib (a tyrosine kinase inhibitor). In addition, pulmonary angioplasty and intensive immunosuppressive therapy may be effective for CTEPH and connective tissue disease-associated PAH, respectively. We briefly review the recent progress in the management of PH. (Circ J 2011; 75: 1801-1810)
論文 | ランダム
- 木質有孔梁の撓みに関する検討
- 岩盤崩落の遠心力模型実験とFEM解析について
- 米国における産業財流通業者に関する一考察
- 労働判例解説 オリンパス事件 配転命令は内部通報への報復であり無効と主張 業務上の必要性とは無関係な報復目的の違法・不当な配転と認定[東京高裁平成23.8.31判決]
- 判例解説 自ら設定した企業行動憲章規定に違反して行われた報復的配置転換の効力 : オリンパス事件[東京高裁平成23.8.31判決]